Adaptation to Digital Technologies, Including Decentralized Clinical Trials
First written in FY2024. 2 of 3 entries say "Advanced", first in 2026-06-02. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In this environment, to respond appropriately to these needs, our group will establish collaborative arrangements with vendors offering a range of solutions, actively consider and promote the introduction of the necessary systems, and strengthen the recruitment and development of personnel who are well versed in both technology and clinical development and can apply that expertise in an integrated manner.」
Measures to address AI, DCTs and related areas have been defined, including collaboration with vendors, system implementation, recruitment and development of personnel, strategic partnerships, and in-house development as needed. - 2026-06-02AdvancedGeneral Meetings of Shareholders
「当社グループでは、様々なソリューションを持つベンダーとの協業体制を確立し、必要なシステムの導入検討・推進を積極的に図るとともに、テクノロジーと臨床開発の双方に精通し、その知見を統合的に活用できる人材の採用・育成を強化してまいります。」
DCT等のデジタル技術への対応について、ベンダー協業、システム導入、人材採用・育成、必要に応じた内製化という実施手段が具体化した。 - FY2024First statedAnnual report
「Demand is increasing for the efficient conduct of clinical trials using digital technologies such as decentralised clinical trials (DCTs). In this environment, our group will expand global partnerships for functions we do not have in-house and bring them in-house as needed, enabling us to address increasingly diverse needs for greater clinical trial efficiency.」
Improving clinical trial efficiency through digital technologies such as DCTs has been added as a new area of focus, using external partnerships and in-house development as needed.